AvidinOx-Lu-177-DOTA-Biotin

Drug Profile

AvidinOx-Lu-177-DOTA-Biotin

Alternative Names: 177Lu-ST2210; AvidinOX®; Oxidised Avidin - sigma-tau; ST2210

Latest Information Update: 23 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sigma-tau SpA
  • Class Antineoplastics; Glycoproteins; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Liver metastases; Lymphoma; Solid tumours

Most Recent Events

  • 01 Jun 2017 Phase-I clinical trials in Lymphoma (Inoperable/Unresectable) in USA (Intralesional) (NCT03188328)
  • 01 Jun 2017 Phase-I clinical trials in Lymphoma (Inoperable/Unresectable) in USA (IV) (NCT03188328)
  • 01 Jun 2017 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable) in USA (Intralesional) (NCT03188328)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top